Nadim Ahmed serves as the President and Chief Executive Officer of Cullinan Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for cancer. With a robust background in the life sciences industry, Ahmed has been instrumental in steering Cullinan Therapeutics towards its mission of transforming patient care through cutting-edge research and development. Prior to joining Cullinan, Ahmed held several high-profile positions, including roles at Novartis and Biogen, where he honed his skills in strategic leadership and operational excellence. At Cullinan Therapeutics, Ahmed has been pivotal in driving the company's growth and innovation. Under his leadership, the company has advanced its pipeline of novel cancer therapies, forging strategic partnerships and securing significant investments to support its research endeavors. Ahmed's vision for Cullinan is to become a leader in oncology, and his strategic initiatives have positioned the company well on this path. His ability to navigate the complex landscape of drug development and his commitment to patient-centric solutions have been key to Cullinan's success. Ahmed's professional achievements extend beyond his current role. He is recognized in the industry for his contributions to advancing healthcare solutions and has been featured in numerous publications and conferences. His educational background includes a degree in biomedical engineering, which has provided him with a solid foundation in the technical aspects of drug development. Ahmed's leadership style is characterized by a collaborative approach, fostering a culture of innovation and excellence at Cullinan Therapeutics.